GLP-1 receptor agonists, CKD, and eGFR trajectory
Author:
Publisher
Elsevier BV
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference6 articles.
1. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial;Tuttle;Lancet Diabetes Endocrinol,2018
2. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes;Muskiet;Nat Rev Nephrol,2017
3. Dulaglutide and renal protection in type 2 diabetes;Cherney;Lancet Diabetes Endocrinol,2018
4. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment;Tonneijck;J Am Soc Nephrol,2017
5. Bardoxolone methyl and kidney function in CKD with type 2 diabetes;Pergola;N Engl J Med,2011
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis;Annals of Medicine & Surgery;2023-08-16
2. Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists;Kidney International;2021-02
3. Novel therapeutic agents for the treatment of diabetic kidney disease;Expert Opinion on Investigational Drugs;2020-09-14
4. Salvaging remote ischaemic preconditioning as a therapy for perioperative acute kidney injury;British Journal of Anaesthesia;2020-01
5. INDIVIDUALIZATION OF RENOPROTECTION IN DEPENDENCE FROM ESTIMATED GLOMERULAR FILTRATION RATE AND RENAL FUNCTIONAL RESERVE;Nephrology (Saint-Petersburg);2019-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3